硅介导的水稻对二化螟幼虫钻蛀行为的影响

采用对二化螟敏感(汕优63)和中抗(盐丰47)的水稻品种,设置硅酸钙处理,观察二化螟蚁螟和三龄幼虫在不同处理稻茎上的钻蛀率、蛀入率和蛀入耗时,同时测定不同处理植株的硅细胞数量及植株与土壤的二氧化硅含量,旨在明确水稻施用硅肥对二化螟幼虫钻蛀行为的影响以及这种影响在不同龄期幼虫和不同抗虫性水稻品种间是否存在差异。蚁螟和三龄幼虫钻蛀率随硅肥施用量增加而降低(幅度为5%—28%)。蚁螟蛀入率在硅肥处理之间和水稻品种之间均没有差异;三龄幼虫蛀入率随硅肥施用量增加而显著下降10%—40%,盐丰47上的蛀入率显著低于汕优63(差异10%—30%)。蚁螟蛀入耗时随硅肥施用量增加而显著延长,三龄幼虫蛀入耗时与品种抗性有显著关系。稻茎硅含量随硅肥施用量增加而增大,并且与三龄幼虫蛀入率呈负相关、与三龄幼虫蛀入耗时呈正相关关系。因此,施用硅肥可直接抑制二化螟幼虫钻蛀,蛀入耗时的延长可间接地延长幼虫暴力于其它防治措施的时间;施用硅肥对三龄幼虫成功蛀入的影响大于对蚁螟的影响;相对于抗虫品种,施用硅肥能在更大程度上增强感虫品种对二化螟幼虫钻蛀行为的抑制作用。     

Targeting ACLY efficiently inhibits SARS-CoV-2 replication

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health challenge the world has witnessed in the past decades. SARS-CoV-2 undergoes constant mutations and new variants of concerns (VOCs) with altered transmissibility, virulence, and/or susceptibility to vaccines and therapeutics continue to emerge. Detailed analysis of host factors involved in virus replication may help to identify novel treatment targets. In this study, we dissected the metabolome derived from COVID-19 patients to identify key host factors that are required for efficient SARS-CoV-2 replication. Through a series of metabolomic analyses, in vitro, and in vivo investigations, we identified ATP citrate lyase (ACLY) as a novel host factor required for efficient replication of SARS-CoV-2 wild-type and variants, including Omicron. ACLY should be further explored as a novel intervention target for COVID-19.     

Ginsenoside Rh2 mitigates doxorubicin‐induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer‐bearing mice

ObjectivesThere are presently a few viable ways to reduce cardiotoxicity of doxorubicin (Dox). The combination of chemotherapy agents with natural compounds delivers greater efficacy and reduces adverse effects in recent researches for cancer treatment. Here, we examined the potential effect of ginsenoside Rh2 on a Dox‐based regimen in chemotherapy treatment.Materials and MethodsHuman breast tumour (MDA‐MB‐231) xenograft nude mice, human cardiac ventricle fibroblasts, and human umbilical vein endothelial cells (HUVEC) were employed in the present study. Histology, immunohistochemistry, immunofluorescence, western blot, antibody array, and RNA‐sequencing analyses were utilized to assess the protective effect of Rh2 on cardiotoxicity induced by Dox and the underlying mechanisms.ResultsRh2‐reduced cardiotoxicity by inhibiting the cardiac histopathological changes, apoptosis and necrosis, and consequent inflammation. Pathological remodelling was attenuated by reducing fibroblast to myofibroblast transition (FMT) and endothelial–mesenchymal transition (EndMT) in hearts. RNA‐sequencing analysis showed that Dox treatment predominantly targets cell cycle and attachment of microtubules and boosted tumour necrosis, chemokine and interferon‐gamma production, response to cytokine and chemokine, and T cell activation, whereas Rh2 regulated these effects. Intriguingly, Rh2 also attenuated fibrosis via promoting senescence in myofibroblasts and reversing established myofibroblast differentiation in EndMT.ConclusionsRh2 regulates multiple pathways in the Dox‐provoked heart, proposing a potential candidate for cancer supplement and therapy‐associated cardiotoxicity.

Doxorubicin is extensively reported to induce severe cardiotoxicity in clinical applications. Our work proposed a natural herbal compound, ginsenoside Rh2, as a potential candidate for attenuating this side effect. Rh2 significantly inhibited cardiac apoptosis and necrosis, inflammation, and pathological remodelling in Dox‐challenged hearts.     

Design,synthesis and biological evaluation of novel diosgenin–benzoic acid mustard hybrids with potential anti-proliferative activities in human hepatoma HepG2 cells

To discover new lead compounds with anti-tumour activities, in the present study, natural diosgenin was hybridised with the reported benzoic acid mustard pharmacophore. The in vitro cytotoxicity of the resulting newly synthesised hybrids (8–10, 14a–14f, and 15a–15f) was then evaluated in three tumour cells (HepG2, MCF-7, and HeLa) as well as normal GES-1 cells. Among them, 14f possessed the most potential anti-proliferative activity against HepG2 cells, with an IC₅₀ value of 2.26 µM, which was 14.4-fold higher than that of diosgenin (IC₅₀ = 32.63 µM). Furthermore, it showed weak cytotoxicity against GES-1 cells (IC₅₀ > 100 µM), thus exhibiting good antiproliferative selectivity between normal and tumour cells. Moreover, 14f could induce G0/G1 arrest and apoptosis of HepG2 cells. From a mechanistic perspective, 14f regulated cell cycle-related proteins (CDK2, CDK4, CDK6, cyclin D1 and cyclin E1) as well mitochondrial apoptosis pathway-related proteins (Bax, Bcl-2, caspase 9, and caspase 3). These findings suggested that hybrid 14f serves as a promising anti-hepatoma lead compound that deserves further research.     

人γ干扰素突变体(rIFN-γ132-PGIL)的构建及其生物学活性的测定

利用DNA重组技术,去掉人γ干扰素(IFNγ)基因3′端含编码多肽羧基(C)端11个氨基酸的核苷酸序列,与编码P,G,I,L的DNA序列相连接,构成IFNγ突变体(rIFN-γ132-PGIL)基因,将后者插入pBV220P_RP_L串连启动子下游,转化大肠杆菌DH5α,在CIts857基因的调节下,通过升温诱导,获得了高效表达,表达量约占菌体可溶性蛋白的30％以上,抗病毒活性平均可达4.9×10~-8U/L,比母体菌株高10倍。SDS—PAGE结果表明,rIFN-γ132—PGIL分子量为17kd。     

GST pull-down验证流感病毒PB1-F2蛋白与热休克蛋白40的相互作用

为体外验证流感病毒PB1-F2与热休克蛋白Hsp40相互作用,通过两个方向的GST pull-down试验验证PB1-F2与Hsp40的相互作用。构建GST-多肽融合蛋白原核表达载体pGEX-6P-1-PB1-F2和pGEX-6P-1-Hsp40,并在大肠杆菌(E.co-li)BL21中诱导表达;构建真核表达载体pLEGFP-Hsp40及pCAGGS-PB1-F2,并分别转染293T细胞使其表达Hsp40及PB1-F2融合蛋白,然后进行GST pull-down试验验证二者的相互作用。成功地构建了两种蛋白的各种表达载体,经表达、纯化获得了可溶性的GST-多肽融合蛋白,GST pull-down试验正反两方向都证实了PB1-F2与Hsp40的相互作用,初步证实了流感病毒PB1-F2在体外能与Hsp40发生相互作用。